ReNeuron Group is a clinical-stage stem cell leader primarily focused on developing novel stem cell therapies to target areas of important unmet or inadequately met medical need. The company has used its stem cell technologies to develop cell-based therapies for significant disease conditions for which cells can be readily administered “off the shelf” to eligible patients without the need of additional immunosuppressive drug treatments. For more information, visit the company’s Web site at www.reneuron.com.

The BIO CEO & Investor Conference is the largest investor conference focused on established and emerging publicly traded biotech companies. Each year the annual event provides a neutral forum where institutional investors, industry analysts, and senior biotechnology executives have the opportunity to shape the future investment landscape of the biotechnology industry. For more information on Biotechnology Industry Organization (BIO), visit www.bio.org.

Let us hear your thoughts below: